WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/094612    International Application No.:    PCT/US2004/012568
Publication Date: 04.11.2004 International Filing Date: 22.04.2004
C07K 16/30 (2006.01)
Applicants: A & G PHARMACEUTICAL, INC. [US/US]; 9130 Red Branch Road, Suite U, Columbia, MD 21045 (US) (For All Designated States Except US).
SUN, Le [US/US]; (US) (For US Only).
SERRERO, Ginette [US/US]; (US) (For US Only).
CORVERA, Joe [US/US]; (US) (For US Only).
HOU, Yodong [US/US]; (US) (For US Only)
Inventors: SUN, Le; (US).
SERRERO, Ginette; (US).
HOU, Yodong; (US)
Agent: LI, Kening; Crowell & Moring, LLP, Intellectual Property Group, P.O. Box 14300, Washington, DC 20044-4300 (US)
Priority Data:
60/464,350 22.04.2003 US
Abstract: front page image
(EN)Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.
(FR)La présente invention concerne de nouveaux anticorps monoclonaux et des fragments de liaison associés spécifiques du cancer du sein, du cancer du poumon, du cancer du côlon et d'autres cancers chez l'homme. L'anticorps monoclonal ne se lie pas à la surface cellulaire de tissus humains normaux. Cette invention a aussi trait à l'antigène ou aux antigènes spécifiques de cancer correspondants ayant un poids moléculaire apparent de 40-52 130-200 kDa, et aux polynucléotides codant l'antigène et les régions CDR de l'antigène, ainsi qu'à des méthodes de diagnostic, de pronostic et de traitement du cancer du sein humain. Lesdits anticorps possèdent une spécificité tumorale et sont utilisés en thérapie, diagnostic, détection et imagerie de cancers. Les antigènes de surface spécifiques de cancer reconnus par les anticorps peuvent servir de cibles dans la détection, le diagnostic, l'inhibition ou l'apoptose de cellules cancéreuses.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)